Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Alpha type recombined human interferon suppository and producing process

A technology of recombinant human interferon and production process, which is applied in suppository delivery, antiviral agent, drug combination, etc., can solve the problems of large side effects and influence of treatment effect, improve curative effect, avoid pain and fever reaction, and be convenient to use Effect

Inactive Publication Date: 2003-11-26
CHANGCHUN CHANGSHENG GENE PHARM CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, for some dosage forms of interferon, due to various side effects caused by systemic administration, the therapeutic effect is greatly affected.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] Take polyethylene glycol 400, polyethylene glycol 1000, polyethylene glycol 1540, polyethylene glycol 4000, polyethylene glycol 6000, 10mmol PB and mix according to a certain proportion, after autoclaving, cool to 40-56 ℃ and add Interferon stock solution, fully mixed, so that the content of interferon is 50-1000IU / ml, the filling volume is 2g / cartridge or 1g / cartridge (for children). 1# formula: polyethylene glycol 1540 33%; polyethylene glycol 6000 47%;

[0018] PB buffer 19%; interferon 1%. 2# formula: polyethylene glycol 1540 70%; polyethylene glycol 6000 29%;

[0019] Interferon 1%. 3# formula: polyethylene glycol 400 29%; polyethylene glycol 1540 30%;

[0020] Macrogol 6000 40%; Interferon 1%. 4# formula: polyethylene glycol 400 26%; polyethylene glycol 1540 26%;

[0021] Macrogol 6000 35%; Interferon 1%;

[0022] PB buffer 12% 5# formula: polyethylene glycol 1000 95%; polyethylene glycol 4000 4%;

[0023] Interferon 1%. 6# formula:...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides type-Alpha recombinant human interferon suppository and its production process. After polyglycol products with different molecular weight are mixed, high pressure sterilized and cooled to 40-56 deg.c, the interferon liquid is added to a content of 500,000-10,000,000 IU / ml, with the mixture being packed. Via rectum or anus administration, the medicine absorbed by rectum mucous membrane is transferred to whole body via rectum vein, portal vein and liver; or via rectum vein, anal canal vein, inferior canal vein and blood circulation system. Or, the medicine may be absorbed by rectum mucous membrane and lymph system. Local administration may reach relatively high local interferon level essential for treating viral intestinal tract disease.

Description

Technical field: [0001] The invention provides an α-type recombinant human interferon suppository and a production process, belonging to the technical field of production of interferon dosage forms. Background technique: [0002] Interferon is currently an effective biological agent for the treatment of various viral diseases at home and abroad. The clinically used interferon dosage forms at home and abroad are mainly interferon injections, eye drops, ointments and other dosage forms. These dosage forms have all obtained good therapeutic effects in clinical application. It has been clinically proven that the higher the concentration of interferon, the better the effect of treating the virus. Therefore, for some dosage forms of interferon, various side effects caused by systemic administration are very large, and the therapeutic effect is greatly affected. Invention content: [0003] The invention provides an α-type recombinant human interferon suppository, which is admin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/02A61K38/21A61P1/00A61P31/12
Inventor 李世军董义兰李晶章春宇
Owner CHANGCHUN CHANGSHENG GENE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com